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ABSTRACT
This work provides new insights into the effects of sulfonated steroids and pharmaceutical 
compounds on cytochromes P450 involved in the steroid hormone biosynthesis. 
At first, the CYP11A1 dependent side-chain cleavage of cholesterol was examined under the 
influence of DHEAS. An augmentation of the catalytic efficiency (75%) of CYP11A1 in the presence of 
DHEAS was demonstrated, which was shown to be a result of a tighter binding of CYP11A1 with its 
redox partner Adx and of a better affinity for its substrate. 
Further, it was investigated whether pregnenolone sulfate (PregS) constitutes a starting compound 
for a potential steroidogenic pathway for sulfonated steroids. The authors provide evidence that 
CYP17A1 hydroxylates PregS at position C17, although no subsequent lyase-reaction could be 
induced in the presence of cytochrome b5. 
Taken together, these findings provide evidence that sulfonated steroids play a more important role 
in the steroid metabolism of mammals than previously assumed. 
In addition, it was possible to elucidate the underlying mechanism of the unequal inhibitory effect of 
the anesthetic compounds etomidate and carboetomidate on the cortisol producing enzyme 
CYP11B1 at a molecular level. Both were shown to interact differently with CYP11B1, which was 
demonstrated by spectroscopic and docking studies, as well as substrate conversion experiments.  
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ZUSAMMENFASSUNG
Diese Arbeit gewährt neue Einblicke in die Wirkungsweise sulfonierter Steroide und 
pharmazeutischer Substanzen auf Cytochrome P450, die an der Steroidhormonbiosynthese beteiligt 
sind. 
Zunächst wurde die CYP11A1-abhängigen Seitenkettenspaltung von Cholesterin unter Einfluss von 
DHEAS untersucht. Es konnte eine Steigerung der katalytischen Effizienz (75%) des CYP11A1 in 
Anwesenheit von DHEAS nachgewiesen werden, die auf eine stärkere Bindung des CYP11A1 mit 
seinem Redoxpartner Adx, sowie einer erhöhten Affinität des Enzyms zu seinem Substrat 
zurückzuführen war. 
Des Weiteren wurde untersucht, ob Pregnenolonsulfat (PregS) eine Ausgangssubstanz für einen 
Stoffwechselweg für sulfonierte Steroide darstellt. Es konnte gezeigt werden, dass CYP17A1 PregS an 
Position C17 hydroxyliert, wobei auch in Anwesenheit von Cytochrom b5 keine Lyaseaktivität 
induziert werden konnte. 
Zusammengefasst zeigen diese Ergebnisse, dass sulfonierte Steroide eine bedeutendere Rolle im 
Steroidmetabolismus spielen als bisher angenommen. 
Ferner wurde der zugrundeliegende Mechanismus für den unterschiedlichen inhibitorischen Effekt 
der Anesthetika Etomidat und Carboetomidat auf das Kortisol bildende Enzym CYP11B1 auf 
molekularer Ebene aufgeklärt. Es konnte durch spektroskopische Versuche, Dockingstudien, sowie 
Substratumstatzexperimente gezeigt werden, dass beide Substanzen mit dem CYP11B1 auf 
unterschiedliche Weise interagieren.  
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1 GENERAL PART 
1.1 INTRODUCTION
CYTOCHROMES P450 
Cytochromes P450 (CYPs) are heme-containing proteins, which can be found virtually 
ubiquitous in organisms from all biological kingdoms. They are extremely versatile enzymes 
catalyzing a huge variety of reactions, such as hydroxylations, N-, O- and S-dealkylations, 
sulphoxidations, epoxidations, deaminations, desulphurations, dehalogenations, 
peroxidations, and N-oxide reductions [1]. CYPs are involved in many biological processes. 
They contribute to the biotransformation of drugs and xenobiotics, are involved in the 
synthesis of steroid hormones, fatty acids, eicosanoids and bile acids, are essential for the 
metabolism of vitamin D, convert alkanes, terpenes and aromatic compounds, and 
participate in the biodegradation of herbicides and insecticides [2]. So far (July 2014), 21,039 
CYP sequences have been identified1. To classify the huge number of CYPs, a systematic 
nomenclature was introduced by Nebert et al. in 1989 [3]: the abbreviation CYP stands for 
cytochrome P450. The number after the CYP indicates the membership to a family (>40 % 
identity of amino acid sequence is required to belong to the same family). The subfamiliy 
(>55% identity of amino acid sequence is required to belong to the same subfamily) is 
displayed by a letter. Then, again a number indicates the corresponding isoenzyme, as 
shown in Figure 1. 
FIGURE 1: NOMENCLATURE OF CYPS EXEMPLIFIED BY CYP17A1.
CYPs were first discovered independently by Klingenberg and Garfinkel in the late 1950s 
[4,5]. They examined liver microsomes from rats and pigs, observing a red pigment with an 
absorption peak at 450 nm in the CO-difference spectrum. But not until 1964 these pigments 
were identified as heme-containing proteins by Omura and Sato [6], with an iron(III)-ion 
bound protoporphyrin XI as prosthetic group. Due to their characteristic absorption 
maximum, they were aptly termed Cytochromes P450. This particular absorbance property 
results from the binding of the fifth ligand of the heme-iron [7], which is the thiolate group 
of a conserved cysteine. Thus, CYPs are categorized as heme-thiolate proteins [8]. The 
general reaction catalyzed by cytochromes P450 is shown in Figure 2.  
1 http://drnelson.uthsc.edu/CytochromeP450.html 
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FIGURE 2: GENERAL REACTION MECHANISM OF CYPS. 
An oxygen atom, delivered from molecular oxygen, is inserted into an aliphatic or aromatic 
compound, while the second oxygen atom is reduced to water. CYPs are classified as 
external monooxygenases, as they require electrons commonly provided by NAD(P)H via 
electron transfer partners to catalyze this reaction. Depending on their cellular localization 
and the type of electron transfer chain, CYPs are assigned to different classes of which ten 
have been described so far [2]. In mammals only two exist: the mitochondrial class I and the 
microsomal class II cytochrome P450 systems (Figure 3). The mitochondrial CYPs are 
arranged at the inner mitochondrial membrane. The electrons needed to carry out their 
hydroxylation reactions are transferred from NADPH via a FAD containing 
ferredoxin/adrenodoxin reductase (AdR) and an iron-sulphur containing 
ferredoxin/adrenodoxin (Adx). In case of the microsomal CYPs, which are attached to the 
endoplasmatic reticulum (ER), the electrons are delivered from NADPH through a FAD and 
FMN containing NADPH-dependent oxidoreductase (CPR).  
FIGURE 3: SCHEME OF MITOCHONDRIAL AND MICROSOMAL CYOTOCHROME P450 REDOX SYSTEMS. A: CLASS I MITOCHONDRIAL 
SYSTEM TRANSFERRING ELECTRONS FROM NADPH VIA ADR AND ADX TO THE CYPS. B: CLASS II MICROSOMAL SYSTEM TRANSFERRING 
ELECTRONS FROM NADPH VIA CPR TO THE CYPS. 
Although the sequence homology between different CYPs can be less than 20 %, their three-
dimensional structure remains strongly conserved. The variable regions are formed by the 
flexible substrate recognition sites and enable CYPs to utilize an extreme diverse range of 
different substrates and to catalyze a big variety of reactions [9]. 
STEROID HORMONE BIOSYNTHESIS
In mammals steroid hormones carry out multiple physiological actions and are indispensable 
for a normal development and reproduction. Their synthesis takes place in steroidogenic 
organs or tissues like the gonads, testes, adrenal gland or the brain. In a series of enzymatic 
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reactions involving six CYPs and three hydroxysteroid dehydrogenases (HSDs), mineralo- and 
glucocorticoids as well as sex hormones are generated (Figure 4). 
FIGURE 4: STEROID HORMONE BIOSYNTHESIS. IN A CASCADE OF REACTIONS, WHERE SIX CYPS AND THREE HSDS PARTICIPATE, 
MINERALOCORTICOIDS, GLUCOCORTICOIDS AND SEX HORMONES ARE FORMED.
In the steroidogenesis, mitochondrial (CYP11A1, CYP11B1 and CYP11B2) as well as 
microsomal (CYP17A1, CYP21A2 and CYP19) CYPs participate. The significance of this 
compartmentalization on the rate of steroid production and the balance of different steroids 
is not fully understood so far. In 2012 Nguyen et al. used mathematical modeling to 
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demonstrate that this localization in different organelles of a cell generates a cellular steroid 
gradient and can influence the balance of the different steroid products [10], thus providing 
a regulatory mechanism. 
The first enzymatic and rate-limiting step of the steroid hormone biosynthesis constitutes 
the CYP11A1 dependent side-chain cleavage of cholesterol (C), yielding pregnenolone (Preg), 
which is the precursor of mineralo- and glucocorticoids, as well as the sex hormones. 
MINERALOCORTICOIDS
The mineralocorticoid pathway is initiated by the conversion of Preg by 3-HSD, which 
oxidizes the 3-hydroxyl group to a keto group and moves the double bond from C5 to C4 
through an isomerase reaction. The formed product progesterone (Prog) is an important 
progestagen involved in embryogenesis, female menstrual cycle and pregnancy and, 
moreover, it serves as substrate for CYP21A2, which hydroxylates Prog at position C21 
yielding 11-deoxycorticosterone (DOC). Via the two intermediates, corticosterone (B) and 
18OH-corticosterone (18OH-B), DOC is converted to aldosterone (Aldo) through two 
hydroxylation and one oxidation steps. Aldo, the main mineralocorticoid, regulates the 
blood- and water-homeostasis through modification of the sodium channels in the kidney. 
Thereby, uptake of sodium and water in the kidney and secretion of potassium occurs, 
leading to an increased blood volume and thus to an increased blood pressure. The 
production of mineralocorticoids is regulated via the renin-angiotensin-aldosterone-system 
(RAAS), as shown in Figure 5 [11].  
FIGURE 5: SCHEMATIC OVERVIEW OF THE RAAS: RENIN IS RELEASED BY THE KIDNEY. ANGIOTENSINOGEN IS CLEAVED BY RENIN, 
YIELDING ANGIOTENSIN I, WHICH IS CONVERTED TO ANGIOTENSIN II BY ANGIOTENSIN-CONVERTING ENZYME. ANGIOTENSIN II 
STIMULATES THE ADRENAL GLAND TO RELEASE ALDOSTERONE [11].
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In mammals, low blood volume stimulates the kidney to release renin directly into the 
circulation. This enzyme converts the peptide hormone angiotensinogen, which is secreted 
by the liver, into angiotensin I. Subsequently, angiotensin I, which serves as substrate for the 
angiotensin-converting enzyme (ACE), is converted to angiotensin II. The latter acts on the 
adrenal cortex, stimulating Aldo secretion and, thus, increasing blood volume. 
GLUCOCORTICOIDS
The pathway for the synthesis of glucocorticoids starts with the CYP17A1-dependent 
hydroxylation of Preg at position C17 (Figure 4). The resulting product 17OH-pregnenolone 
(17OH-Preg) is further metabolized to 17OH-progesterone (17OH-Preg) by 3-HSD. 17OH-
Prog can also be formed from Prog via a 17-hydroxylation by CYP17A1. Afterwards, this 
steroid metabolite is converted to 11-deoxycortisol (RSS) through a hydroxylation at C21 by 
CYP21A2, which is then transformed into cortisol (F) by CYP11B1, catalyzing a hydroxylation 
at position C11. F, the main glucocorticoid is released in response to stress in mammals and 
possesses a wide spectrum of functions. It is involved in the stimulation of the 
gluconeogenesis in the liver to increase the blood sugar and has a catabolic effect on fat and 
protein metabolism. Cortisol availability is regulated through the hypothalamic-pituitary-
adrenal (HPA) axis as shown in Figure 6. 
FIGURE 6: SCHEME OF THE HPA AXIS: STRESS INDUCES THE RELEASE OF THE CORTICOTROPIN RELEASING HORMONE (CRH) FROM THE 
HYPOTHALAMUS. CRH STIMULATES THE PITUITARY GLAND TO SECRETE THE ADRENOCORTICOTROPIC HORMONE (ACTH), WHICH 
STIMULATES THE ADRENAL GLAND TO PRODUCE CORTISOL. 
 Stress, illness, physical activity, low cortisol levels and the circadian rhythm stimulate the 
hypothalamus to secrete corticotropin-releasing hormone (CRH). CRH is transported to the 
pituitary gland, where it induces the secretion of the adrenocorticotropic hormone (ACTH). 
The latter enters the blood circulation to reach the adrenal cortex. There, ACTH interacts 
with its corresponding receptors, inducing cholesterol delivery into mitochondria and 
expression of CYP11A1, CYP11B1 and their corresponding electron transfer partners Adx and 
AdR [12]. As a consequence, F production and release are enhanced. 
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SEX HORMONES
The formation of sex hormones commences with the synthesis of dehydroepiandrosterone 
(DHEA). CYP17A1 is capable to catalyze a lyase reaction utilizing 17OH-Preg as substrate, 
yielding DHEA. Multiple beneficial properties are ascribed to DHEA, such as prevention of 
osteoporosis, anti-obesity action, prevention of atherosclerosis, anti-carcinogenic properties 
and more [13]. In addition, DHEA represents the precursor of androgens and estrogens, 
which can be metabolized to androstenedione (Andro) by 3-HSD. Andro can also be formed 
from 17OH-Prog via a lyase reaction by CYP17A1. This intermediate serves as substrate for 
CYP19, which eliminates the methyl group at C19 through three consecutive hydroxylations 
at this position, yielding estrone (E1). E1 can further be metabolized to estradiol (E2) by 17-
HSD, which reduces the keto group at position C17 to a hydroxyl group. E1 and E2 are the 
main estrogens in mammals. They are present in both genders but in significant higher 
concentrations in female. Principally, they induce the development of the female secondary 
sexual characteristics and regulate the female menstrual cycle. In addition, they are 
important for the maturation of sperm in male [14]. Moreover, Andro can be converted into 
testosterone (T) by 17-HSD, and then, after reduction by 5-reductase to dihydro-
testosterone. T and dihydrotestosterone are the main androgens with higher concentrations 
in male. They are crucial for the development of male secondary sexual characteristics like 
increased muscle and bone mass, as well as the growth of body hair. 
Similar to the HPA-axis for cortisol regulation, androgen availability is controlled by the 
hypothalamic-pituitary-gonadal (HPG)-axis. The hypothalamus secretes gonadotropin-
releasing hormone (GnRH), which stimulates the pituitary gland to release luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH). LH induces testicular T production, 
which causes a negative feedback loop resulting in GnRH and LH inhibtion [15].  
The action of T is further enhanced by the effect of FSH, which stimulates cells to express 
androgen receptors. In female, the feedback effect of different steroid hormones changes 
depending on the stage of the menstrual cycle. Progesterone and estradiol, which are 
released during the postovulatory phase, inhibit LH and FSH secretion. In the late luteal 
phase, FSH and FH levels increase, as progesterone and estrogen production decrease, 
leading to the recruitment of a new follicle. The growing follicle starts to release increasing 
amounts of estrogens in the follicular growth phase, which slightly inhibit LH and FSH 
secretion. Afterwards, in the preovulatory surge phase, preparing for ovulation, increased 
amounts of LH and FSH are released. It is thought that further elevation of estrogens results 
in a switch from inhibitory feedback to activatory effect of estrogens onto LH and FSH 
production. When the egg is released, increasing amounts of progesterone are produced, 
leading to inhibition of LH and FSH release. During conception, the fetus takes over 
progesterone production, preventing a new ovulation. 
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COMPARTMENTALIZATION OF STEROID HORMONE SYNTHESIS
The production of mineralo- and glucocorticoids, as well as sex hormones, takes place in 
different zones in steroidogenic tissues of different organs, supporting the regulation of the 
production of distinct steroid hormones [10]. The most striking example is the adrenal gland, 
consisting of different zones, each producing different steroid hormones (Figure 7). The zona 
glomerulosa expresses CYP11A1, CYP21A2 and CYP11B2, but lacks to express CYP17A1, 
which is essential for glucocorticoid and sex hormone production. Thus, this zone is solely 
designated to synthesize mineralocorticoids. As this adrenal area possesses angiotensin II 
receptors, the aldosterone production is under control of the renin-angiotensin system 
(Figure 5).  
Further, in the zona fasciculata, CYP17A1, CYP21A2 and CYP11B1 are found, whereas 
CYP11A1 and cytochrome b5, which is essential to induce the lyase activity of CYP17A1, are 
not expressed. In addition, ACTH receptors are synthesized in this zona. The presence of 
CYP17A1 and the absence of cytochrome b5 lead on to the production of glucocorticoids, like 
cortisol, which is regulated by the HPA-axis (Figure 6).  
The androgens DHEA and androstenedione are produced in the zona reticularis of the 
adrenal gland. Here, CYP21A2 and CYP11B1 are expressed in very small quantities, in 
contrast to CYP17A1 and cytochrome b5, which are synthesized in large amounts increasing 
the capability of CYP17A1 to scissor the 17,20 carbon carbon bond of 17OH-Preg, yielding 
DHEA. As 3-HSD is also produced there in small quantities, androstenedione can be 
synthesized from DHEA in a small extend. 
Further metabolism to estrogens and androgens takes place in reproductive tissues like the 
gonads or the testes.  
FIGURE 7: ADRENAL GLAND HISTOLOGY DIAGRAM: PRODUCTION OF STEROID HORMONES TAKES PLACE IN THE THREE DIFFERENT 
ZONES OF THE ADRENAL GLAND2.
2 http://www.normalhistology.com/wp-content/uploads/Adrenal-Gland-Histology-Diagram.gif
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EFFECT OF STEROID HORMONE METABOLISM DISORDERS
Steroid hormones are very important endogenous compounds indispensable for mammalian 
vitality. Their concentrations in organisms are strictly controlled at different levels. 
Alterations in the activities of steroidogenic CYPs leading to changed steroid hormone levels 
often cause severe diseases. One of the most common steroid metabolism disorder in 
humans is the congenital adrenal hyperplasia (CAH). The symptoms of affected persons vary 
depending on the altered steroidogenic CYP. In over 90 % of cases the deficiency of CYP21A2 
is responsible for causing CAH. This enzyme is crucial for the synthesis of mineralocorticoids 
and glucocorticoids. For this reason, aldosterone and cortisol production are reduced and 
thus the control of salt balance and body fluid volume as well as the glycemic control and 
stress response are altered [16]. In the case of a complete loss of CYP21A2 activity, patients 
suffer from salt-wasting, absence of mineralo- and glucocorticoids as well as an increased 
level of androgens resulting in virilization of females and enlarged genitalia in males. 
Moreover, ACTH release is strongly increased due to a loss of the feedback inhibition by 
cortisol. The permanent stimulation of the adrenal gland to express steroidogenic CYPs 
provokes growth of this organ, resulting in a hyperplasia. The range of these symptoms 
depends on the degree of CYP21A2 activity alteration and it reaches from the described 
severe forms to mild forms with slight virilization in females and nearly no symptoms in 
males, without reduced aldosterone and cortisol levels in both genders. In many cases the 
fertility of females is reduced. 
CYP11B1 catalyzes the last step in the cortisol production. It hydroxylates 11-deoxycortisol at 
position C11, yielding cortisol. Deficiencies of the CYP11B1 enzyme account for 5-8 % of 
patients suffering from CAH. A decreased cortisol production leads to elevated androgen and 
aldosterone levels, resulting in virilization and hypertension. Further, glucocorticoid-
dependent biological functions such as delivery of sugar to the blood and regulation of the 
immune system might be altered. 
An impairment of CYP11B2 activity, which is essential for aldosterone synthesis, provokes 
severe salt loss and patients suffer from vomiting and failure to thrive. There are two 
different CYP11B2 deficiencies described: corticosterone methyl oxidase (CMO) deficiency 
type I and type II. Their classification depends on the altered activity of CYP11B2. This 
enzyme catalyzes three distinct reactions, hydroxylation at position C11, followed by 
hydroxylation at position C18 and, finally, oxidation at C18. Patients with an altered 
hydroxylase activity are categorized to CMO-deficiency type I, in contrast to CMO type II, 
where the patients have an impaired oxidase activity of CYP11B2.  
CYP17A1 catalyzes two different reactions: a 17-hydroxylation, yielding 17-hydroxy-
pregnenolone or 17-hydroxy-progesterone, and a 17,20 lyase reaction, yielding DHEA and 
androstenedione. Deficiencies of both CYP17A1 activities cause decreased levels of cortisol 
and androgens, leading to an elevated level of mineralocorticoids. As a consequence, 
patients suffer from hypertension, hypercalemia and hyponatremia. Furthermore, males 
exhibit intersexual genitalia after birth and females develop a primary amenorrhea. In the 
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case of CYP17A1 lyase activity deficiency, only decreased levels of androgens are registered, 
without impact on the level of glucocorticoids.  
Deficiencies of CYP19A1 result in a decreased production of estrogens. Males are nearly not 
affected, but females are virilized after birth and exhibit amenorrhea. Moreover, patients of 
both genders suffering from CYP19A1 deficiency grow tall, as estrogen is crucial to close the 
epiphyseal lines. 
Relationships between testosterone and prostate cancer as well as estrogens and breast 
cancer are well documented. Therefore, CYP17A1 and CYP19A1 are targets in anti-cancer 
therapy and the development of specific inhibitors of these enzymes are of great 
importance. One challenge to create such inhibitors is to avoid cross-reactivity with other 
steroidogenic CYPs. As x-ray structures of both human CYP17A1 [17] and human CYP19A1 
[18] have been recently obtained, new improved inhibitors for prostate and breast cancer 
treatment might be developed. 
SULFONATED STEROIDS
In mammalian organisms, sulfonated steroids often exist in notably higher concentrations 
than unconjugated steroids [19-21]. As the classical endocrine dogma suggests that steroids 
must be available in an unconjugated form in order to interact with their corresponding 
receptor to induce a biological response, sulfonated steroids were regarded for a long time 
to be inactive and to be solely designated for renal or biliary excretion [22-26]. Interestingly, 
especially during pregnancy, human and other mammals exhibit highly elevated levels of 
estrone sulfate (E1S) [19,21] and pregnenolone sulfate (PregS) [27] indicating a crucial role 
of these conjugated steroids in reproduction, which still has to be elucidated. In the last 
decades, sulfonated steroids were considered to act as precursors for unconjugated steroids, 
as they can be hydrolyzed by steroid sulfatases [28]. In 2008, Schuler and colleagues 
discovered that estrogen receptors, sulfotransferases and steroid sulfatases are expressed in 
the same tissue, strengthening the hypothesis that sulfonated steroids are an important 
alternative source for the local formation of biologically active steroids [29]. This 
demonstrates that the supply of active steroid hormones is not solely regulated by a 
superior system such as the RAAS or the HPA axis for aldosterone and cortisol supply. Due to 
the existence of steroid sulfatases (StS) in certain tissues, a secondary system monitoring the 
availability of unbound, active steroids on a cellular level might exist. In order to be 
hydrolyzed, sulfonated steroids first have to enter cells expressing StS. As their negatively 
charged sulfate moiety hinders a passive diffusion across cell membranes, steroid sulfates 
need to be actively transported by carriers. Transporters of the SLC or SLCO family [30-32] 
were identified to possess high specificity towards steroid sulfates, proving the existence of 
such a secondary system that controls the availability of biologically active steroids. The 
transport and metabolism of steroid sulfates is displayed in Figure 8. Free steroids enter the 
cell by a passive diffusion across the cell membrane or are synthesized endogenously from 
cholesterol. Afterwards, they are able to interact with their receptor and, thus, either induce 
a biological answer or they can be sulfonated by SULTs. Further, these sulfonated steroids 
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can be actively transported out of the cell by carriers or be hydrolyzed by StS, again yielding 
unbound steroids. 
FIGURE 8: METABOLISM AND TRANSPORT OF STEROID SULFATES. (1) CHOLESTEROL IS TRANSPORTED INTO THE MITOCHONDRIA 
INITIATING THE STEROID HORMONE BIOSYNTHESIS. (2) FREE STEROIDS ARE SULFONATED VIA SULFOTRANSFERASES (SULT). (3) 
SULFONATED STEROIDS ARE HYDROLYZED VIA STEROID SULFATASES. (4) STEROID SULFATES ARE TRANSPORTED INTO CELLS VIA 
TRANSPORTERS SUCH AS THE SODIUM DEPENDENT ANION TRANSPORTER (SOAT). 
While the knowledge about physiological features of sulfonated steroids is still sparse, 
research on their biological role has increased in the last years, demonstrating that they are 
versatile compounds involved in many different biological processes. Cholesterol sulfate (CS) 
activates protein kinase C in differentiating keratinocytes, thus being essential for the 
keratinization [33,34].  
PregS displays extremely varying concentrations in humans, with highest levels during birth 
and pregnancy, indicating an important role in mammalian reproduction, which is not clear 
yet. Nevertheless, it was shown that PregS modulates a big diversity of ion channels, 
transporters, and enzymes [27]. 
DHEAS, one of the most abundant steroids in human, was shown to inhibit thrombin-
dependent platelet aggregation and thrombin-dependent activation of Akt, ERK1/2, and p38 
MAP kinase. Thus, DHEAS could possibly be of physiological relevance when functionality of 
the vascular endothelium is compromised, as Bertoni et al. suggested [35]. In addition, 
DHEAS stimulates the proliferation of bovine chromaffin cells, acting through a receptor 
other than the classical steroid receptors, as demonstrated by Sicard et al. [36]. Recently, 
Shihan et al. were able to reveal a non-classical signaling pathway in spermatogenic cells 
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induced by DHEAS [37]. These findings put sulfonated steroids into a new focus of interest. 
From an inactive compound, determined for excretion, to a reservoir for biologically active 
steroids, the functions of these compounds in mammalian organisms had to be completely 
reassessed.  
SULFOTRANSFERASES AND STEROID SULFATASES
Steroid sulfates are generated via a sulfonation reaction catalyzed by three distinct 
sulfotransferases (SULT1E, SULT2B1, SULT2A1). The general reaction mechanism exemplified 
by the sulfonation of DHEA is shown in Figure 9. 
FIGURE 9: REACTION OF A STEROID SULFONATION. DHEA IS SULFONATED BY SULT2A1 AT THE 3-HYDROXYL GROUP. THE SULFONATE 
MOIETY IS PROVIDED BY 3-PHOSPHOADENOSINE-5-PHOSPHOSULFATE (PAPS).
Sulfonation describes the transfer of a sulfonate group (SO3), which is provided by the 
universal sulfonate donor 3-phosphoadenosine 5-phosphosulfate (PAPS). The SO3 group-
transfer to the 3-hydroxyl group of steroids generates an SO4 moiety. For this reason, 
sulfonated products have been incorrectly named sulfates, a nomenclature often used in 
literature [38]. 
SULT1E1 exhibits high affinity for estrogens [39], but was also shown to sulfonate DHEA and 
Preg [40]. It was detected at protein level in the liver [41], endometrium [40], jejenum [42] 
and mammary epithelial cells [43].  
There are two isoforms of SULT2B1: SULT2B1a and SULT2B1b. They are formed through 
alternative splicing, resulting in differences at the N-terminus of the synthesized proteins. 
These differences of the SULT2B1 isoforms lead to distinct substrate selectivities. SULT2B1a 
shows a high specificity towards Preg, whereas SULT2B1b is highly selective for C. RNAs 
encoding SULT2B1 enzymes have been detected in the placenta, trachea, prostate [44], skin, 
vagina, oral mucosa, colorectal mucosa [45] and other tissues [27]. 
SULT2A1 is the best examined human SULT, as its cDNA from liver was already cloned and 
expressed in the early 1990s [46,47]. It favors to sulfonate DHEA, which is considered to be 
the major substrate of SULT2A1, but there a many other steroids serving as substrates, such 
as Preg, C, E1 and E2 (3-hydroxyl group is sulfonated), as well as T and E2 (17-hydroxyl 
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groups are sulfonated). SULT2A1 was found to be expressed in the liver, adrenal gland, 
jejunum [48] and ovary [49] in large quantities. 
The equilibration between sulfonated and unbound steroids is on one hand, regulated by 
the SULT enzymes, which catalyze a sulfonate transfer to free steroid hormones, and, on the 
other hand, by steroid sulfatases (StS), which hydrolyze sulfonated steroids, yielding 
unbound steroids. StSs are considered to be almost ubiquitously present in small quantities 
in mammals. In contrast to the cytosolic SULTs, the StSs are attached to the endoplasmatic 
reticulum. The putative mechanism of StS for the hydrolysis of E1S to E1 is illustrated in 
Figure 10. 
FIGURE 10:  SUGGESTED REACTION FOR HYDROLYSIS OF ESTRONE SULFATE BY STS VIA: I) DESULFATION, CATALYZED BY THE NON-
ESTERIFIED HYDROXYL GROUP, FOLLOWED BY THE ATTACK OF A MOLECULE OF WATER ON FORMYLGYCINE (FGLY); AND II) A DIRECT 
ATTACK OF A MOLECULE OF WATER ON THE SULFUR ATOM OF FGLYS [28]. 
In a first step, the gem-diol form of formylgycine (FGly) from FGlyS is regenerated via 
desulfation (i), catalyzed by the non-esterified hydroxyl group, followed by the attack of a 
water molecule on the FGly intermediate; or by a direct attack of a water molecule on the 
sulfur atom of FGlyS (ii). One of the hydroxyl groups of -CH(OH)OH then attacks the sulfur 
atom of estrone sulfate, yielding estrone and regenerating FGlyS as a consequence [28]. The 
formylglycine residue is unique in StS and other sulfatases and is generated through a 
posttranslational modification of a conserved cysteine residue [50]. 
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1.2 AIMS AND SCOPE
Recombinantly expressed and purified steroidogenic CYPs allow investigations of the impact 
of diverse compounds on their activities, such as inhibitors or endogenous substances, on a 
molecular level. Although the expression of functional steroidogenic CYPs in bacteria still 
remains challenging, the six CYPs participating in steroid hormone biosynthesis were 
reported to be successfully expressed and purified [51-56]. Global aim of this work is the 
expression of high yields of functional steroidogenic CYPs and their redox partners for 
investigating the impact of sulfonated steroids and pharmaceutical compounds on the 
respective reactions. Therefore, bacterial expression, purification and reaction conditions for 
CYP11A1, CYP17A1, CYP11B1, cytochrome b5 and their respective reaction partners had to 
be established and/or optimized. 
Several steroid hormones exist in a sulfo-conjugated form, often in concentrations exceeding 
the unbound form manifold. Investigations on their biological function increased in the last 
decades, but, so far, it has not been considered that sulfonated steroids might interact with 
enzymes involved in steroidogenesis. Thus, their possible contribution to the regulation of 
the production of steroid hormones on the cellular level has not been investigated. In order 
to elucidate their impact, the influence of sulfonated DHEA on the activity of mitochondrial 
CYP11A1 was investigated in a reconstituted in-vitro system utilizing purified CYP11A1 and 
its electron transfer partners, Adx and AdR. Experiments were performed to clarify whether 
DHEAS binds to the enzyme and competes with the natural substrate cholesterol, acting as 
an inhibitor. Further, it had to be elucidated, whether the interaction between CYP11A1 and 
its redox partner, Adx, is influenced in the presence of DHEAS, due to its amphipathic 
structure.  
In terms of the metabolism of sulfonated steroids, it is known that CS is converted to PregS 
in a CYP11A1-dependent reaction [57]. Further metabolism of PregS has not been studied so 
far in detail. Therefore, the subsequent conversion of PregS was explored in a reconstituted 
in-vitro system using purified CYP17A1 and its electron transfer partner, CPR. We aimed to 
determine the kinetics and binding parameters as well as the effect of cytochrome b5, which 
is known to enhance the CYP17A1 dependent lyase reaction. Furthermore, to reveal a 
putative physiological relevance of PregS metabolism, a human cell culture system, 
recombinantly expressing CYP17A1 and CPR, was applied.  
In addition, interference of pharmaceutical substances with the endocrine system, in 
particular with the cortisol production, has been investigated. The anesthetic agent 
etomidate is known to inhibit cortisol production, whereas its derivative carboetomidate 
only slightly alters cortisol synthesis. In this work, the hypothesis was proved, whether 
etomidate and carboetomidate differentially bind to CYP11B1, the cortisol producing 
enzyme. Therefore, cell culture experiments as well as kinetic and binding studies with 
purified CYP11B1 were conducted to elucidate this issue. 
Publications 
16 
2 PUBLICATION OF THE RESULTS 
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3 DISCUSSION AND CONCLUSIONS
EFFECT AND ROLE OF SULFONATED STEROIDS ON STEROIDOGENIC CYPS
The studies comprising this work illustrate for the first time the influence of sulfonated DHEA 
and Preg on the biosynthesis of steroid hormones. The obtained results give insight into a 
crucial mechanism for the regulation of the steroidogenesis in mammals. 
Many important steroid hormones are present in a sulfo-conjugated form, often in 
concentrations exceeding the unbound form by many folds. The sulfonation of unbound and 
hydrolysis of sulfonated steroids constitute an additional regulatory system of 
steroidogenesis, modulating the availability of unbound and thus active steroid hormones. 
The relevance of this mechanism can be observed in patients with a defect of the involved 
enzymes. Concerning the sulfonation, PAPS synthase deficiency manifests in an 
accumulation of unconjugated DHEA in the adrenal, leading to an increase of androgens and 
thus females are virilized, displaying advanced bone age, and suffer from amenorrhea. As a 
result of defects of a sulfatase, sulfonated steroids are enriched in skin, generating x-linked 
ichtiosis. However, this mechanism is not fully understood so far.   
In the last decades, sulfonated steroids have been considered to mainly serve as reservoir 
for inactive steroids, without exerting a direct biological function. So far, the interaction of 
these compounds with enzymes involved in steroidogenesis and their influence on steroid 
hormone production have not been investigated. In the first two publications forming this 
work, evidence is provided for the vital role of sulfonated steroids in the mammalian 
steroidogenesis. In publication 2.1 a new regulatory role of sulfonated steroids in steroid 
hormone biosynthesis was elucidated, demonstrating that DHEAS directly increases CYP11A1 
activity and, thus, modulates the production of steroid hormones. Moreover, it was shown 
that PregS was converted into 17OH-PregS by CYP17A1 giving new insights into the 
metabolism of sulfonated steroids by steroidogenic CYPs (publication 2.2). In mammals the 
steroid hormone biosynthesis displays interesting differences between species. For example, 
the absence of cortisol in the blood of mice is well known, whereas for human and other 
mammal´s health, a considerable cortisol concentration in blood is absolutely required. It 
seems that DOC fulfills the cortisol action in mice. Moreover, concerning the CYP17A1 
activity, there are interspecies differences, with either the 5-, or 4-pathway being 
dominant. Human, bovine, bison, goat, sheep and cat only accept 5 steroids for the 
formation of sex hormones, whereas guinea pig uses 4 steroids for this purpose. Horse, 
hamster, pig and rat are able to utilize both 5 and 4 steroid for sex hormone synthesis [58]. 
In the first two publications, the experiments were performed using bovine proteins. Bovine 
proteins have been explored for a longer time compared with the human ones, and although 
the steroidogenic CYPs of bovine and human show differences in substrate affinities and 
catalytic efficiencies their molecular mechanism is well comparable, as both species undergo 
the 5-pathway for sex hormone production. For these reasons, the bovine system was 
chosen as model organism.  
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It was demonstrated that under the influence of DHEAS the activity of CYP11A1 is 
significantly increased due to an enhanced interaction of CYP11A1 and Adx, as well as an 
elevated substrate affinity of CYP11A1 for cholesterol (Publication 2.1). Based on these 
results, additional experiments were performed to investigate whether DHEAS exhibits a 
regulatory effect on further steroidogenic CYPs (appendix). Its potential effects on CYP17A1, 
the crucial CYP for the production of sex hormones and glucocorticoids, as well as on 
CYP21A2, which is essential for mineralo- and glucocorticoid production, were examined. 
The obtained results showed a slight, but statistically not significant inhibitory effect of 
DHEAS on the 17-hydroxylation activity of CYP17A1 and no effect on CYP21A2. These 
findings suggest that the influence of DHEAS on steroidogenic CYPs might be highly selective. 
The main differences between the mitochondrial CYP11A1 and the microsomal CYP17A1 and 
CYP21A2 are their cellular localization and interaction with the respective electron transfer 
partners. Additional studies are required to explore, whether the impact of DHEAS might be 
restricted to mitochondrial CYPs, to CYP11A1 alone or if it depends on the redox partners. As 
Pechurskaya et al. showed, CYP17A1 is able to utilize the mitochondrial AdR and Adx as an 
electron transfer chain for its substrate conversion [59]. Therefore, it would be of interest to 
investigate whether DHEAS affects the activity of CYP17A1 with these redox partners. 
Additionally, in-vitro experiments with the mitochondrial CYP11B1 and CYP11B2 should be 
performed. If the activity would be influenced, DHEAS might act in a different manner on the 
different CYP classes. In the case of no effect, DHEAS might constitute a highly selective 
compound acting solely on CYP11A1. 
In summary, the enhanced activity of CYP11A1 in the presence of DHEAS was clearly 
demonstrated at the molecular level, providing new insights about regulatory features of 
sulfonated steroids on steroidogenic CYPs. 
To establish a physiological relevance of these findings, cell culture experiments on the 
effect of DHEAS were carried out using the SOAT-HEK293 cell line, expressing CYP11A1 and 
its redox partner, Adx. Due to the low uptake of the extremely unpolar cholesterol into the 
cells, 22(R)-OH-cholesterol, the first hydroxylated intermediate of the CYP11A1-dependent 
reaction was used as an alternative substrate and proved to be converted to pregnenolone 
to a high extent. Interestingly, the presence of DHEAS did not affect the activity of CYP11A1 
regarding this reaction; neither in cell culture nor in the reconstituted in-vitro system. 
Although the previous findings with cholesterol as substrate could not be confirmed, these 
results give additional information about the mechanism of DHEAS action on CYP11A1 
indicating that only the first of the three hydroxylation steps catalyzed by CYP11A1 is 
affected by DHEAS (Figure 11). 
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FIGURE 11: CONVERSION OF C INTO PREG BY CYP11A1, SHOWING ALL THREE HYDROXYLATION STEPS. DHEAS SEEMS TO HAVE AN 
EFFECT ONLY ON THE FIRST HYDROXYLATION STEP.
In order to explore whether the regulatory mechanism of DHEAS on the steroid hormone 
biosynthesis might have a physiological impact, further studies still have to be done using an 
in-vivo model that allows uptake of cholesterol, for instance through the expression of the 
steroidogenic acute regulatory protein StAR, responsible for cholesterol transport, at the 
cells surface. Taken together, steroid hormone delivery underlies a complicated regulation 
at different levels to ensure the optimal dosage of required steroids, and these results 
demonstrate an additional regulatory mechanism at the cellular level. The findings show 
that, in the presence of DHEAS, the first step in the steroidogenesis is enhanced resulting in 
an increased Preg formation, whereas CYP17A1, which is crucial for glucocorticoid and sex 
hormones formation as well as CYP21A2, which is essential for gluco- and mineralocorticoid 
synthesis, are not affected. As a consequence DHEAS might promote the formation of all 
three steroid hormone classes: the mineralo- and glucocorticoids as well as the sex 
hormones. The dosage of DHEAS required in mammalian organism to prompt these effects is 
not possible to anticipate. Therefore, data obtained from animal or human studies are 
needed, showing the steroid profile before and after the intake of different concentrations 
of DHEAS.   
Furthermore, from the biotechnological point of view, DHEAS might be an interesting 
compound for substrate conversions with CYP11A1, as its catalytic activity is strongly 
increased in the presence of this sulfonated steroid. 
Besides the impact of sulfonated steroids on the natural substrate conversion of 
steroidogenic CYPs, the ability of PregS and 17OH-PregS to serve as substrates for CYP17A1 
was assessed. So far, only CS was shown to be converted by CYP11A1 [57,60] and to be 
present in rat adrenal mitochondria [61]. Publication 2.2 focuses on the conversion of PregS 
in a reconstituted in-vitro system with purified CYP17A1 and CPR, as well as in a SOAT-
HEK293 cell culture system. Binding studies were performed and the kinetic parameters of 
CYP17A1-dependent PregS conversion were elucidated, revealing PregS to be a substrate for 
CYP17A1, yielding 17OH-PregS. Moreover, it was demonstrated, that CYP17A1 only performs 
the 17-hydroxylation reaction using PregS, whereas the 17,20 lyase activity could not be 
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activated, even when cytochrome b5 was added to the system. This finding implies that the 
metabolism of PregS does not contribute to the production of sex hormones. To elucidate 
whether 17OH-PregS is an end-product of the steroidogenic pathway for sulfonated steroids 
or it possibly undergoes the pathway for production of glucocorticoids, it was aimed to 
convert 17OH-PregS with purified CYP21A2. This steroidogenic CYP hydroxylates 17OH-Prog 
at position C21 yielding 11-deoxycortisol. Therefore, the expected product when using 
17OH-PregS as substrate would be sulfonated 11-deoxycortisol. However, it was not possible 
to detect any product formation (not shown). Hence, we postulate an alternative 
steroidogenic pathway for sulfonated steroids, starting from CS and ending with 17OH-
PregS. 
The results obtained from the conversion of PregS, which circulates in large quantities with 
varying concentrations during the mammalian life cycle, lead to the conclusion that 
considerable amounts of 17OH-PregS may exist in mammalian organism. These 
concentrations might vary during life, similar to those of its substrate PregS. This speculation 
still needs to be proved, as there are no detailed studies about concentrations of 17OH-
PregS in human or other mammals. In order to quantify the achieved concentrations of 
17OH-PregS from the PregS conversion experiments, this work describes an analytical 
method to quantify this sulfonated steroid metabolite via LC/MS-MS for the first time. This 
method can be applied to determine 17OH-PregS levels in humans and other mammals. 
Whether 17OH-PregS exhibits a physiological meaning in mammals still remains to be 
explored. On one hand, it might act as a reservoir for free 17OH-Preg, and, thus, constitute a 
precursor for glucocorticoids and sex hormones. In contrast, the desulfonation of PregS 
leads to Preg, which is a precursor for all three steroid hormone classes. This fact makes 
17OH-PregS a more specific precursor compared with PregS. Taken the plasma 
concentrations of the steroid hormones into account, it might be reasonable to provide a 
precursor designated for the synthesis of glucocorticoids or sex hormones such as cortisol or 
testosterone, which achieve a plasma concentration of 12 µg/ 100 ml and 0.7 µg/ 100 ml, 
being many folds higher compared with the mineralocorticoid concentrations such as 
aldosterone (0.0068 µg /100 ml) [62]. On the other hand, 17OH-PregS might fulfill biological 
functions similar to the ones described for PregS, such as modulating ion channels or, more 
general, acting as a neurosteroid [27]. However, these assumption needs to be explored, as 
so far no studies have been published referring to the physiological impact of 17OH-PregS in 
mammals. 
Taken together, the results achieved from the reconstituted in-vitro and from the cell culture 
experiments both showing an efficient conversion of PregS to 17OH-PregS, suggest that this 
reaction is not an artificial observation, but might be of physiological relevance. 
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EFFECT OF PHARMACEUTICAL COMPOUNDS ON CYP11B1 
This work focuses on the effect of two anesthetic agents on CYP11B1, the cortisol producing 
cytochrome P450, and provides data about their mechanistic action. 
Alterations of the regulatory system of steroid delivery can lead to a modified steroid profile 
deviating from normal range, with severe consequences for the affected organism. These 
changes can be generated by xenobiotics that directly interact with steroidogenic enzymes, 
influencing their catalytic properties. These types of substances are denominated endocrine 
disruptors, as they modulate the level of required steroids, mostly having a negative effect 
on the organism. 
In terms of the development of new drugs it is of particular significance to minimalize side-
effects, such as interferences with the endocrine system, without impairing their mode of 
action. Etomidate, an anesthetic compound acting on GABA-receptors, has been used as 
sedative for more than 25 years [63]. Due to its high affinity towards CYP11B1, suppressing 
cortisol synthesis and, thus, altering a wide range of biological functions such as stress 
response and immune defense, etomidate cannot be administrated for a long time period 
and has to be replaced by other sedatives. To elude these side-effects, Cotten and 
colleagues [64] designed an etomidate analog, carboetomidate, which exhibits similar 
anesthetic features without influencing the activity of CYP11B1. Using two different 
approaches, it was shown in our studies that etomidate and carboetomidate differentially 
bind to CYP11B1. At first, a kinetic competition assay between photolabeling and ligand 
binding was performed, demonstrating that etomidate, and not carboetomidate, inhibits 
photoincorporation of azi-etomidate. Secondly, spectroscopic studies showed the 
interaction of etomidate with the active site of CYP11B1, whereas carboetomidate did not 
induce any spectral change of CYP11B1, suggesting no interaction with the enzyme.  
In summary, this work presents a novel experimental procedure to investigate whether 
pharmaceutical compounds influence the cortisol production. The methods established in 
this study could be applied to other steroidogenic CYPs such as CYP17A1 and CYP19A1, as all 
of them can be recombinantly expressed and purified, and constitute promising targets in 
anti-cancer treatments. Further, the spectroscopic studies of this work represent an efficient 
screening system for inhibitors or interacting compounds for CYPs. For example, in cases of 
congestive heart failure and myocardial fibrosis, it is of interest to develop CYP11B2 
inhibitors to reduce the aldosterone level in humans, which do not interact with CYP11B1, 
and thus influence the cortisol level. In our study, the described experiments could serve to 
examine the cross reactivity with other steroidogenic CYPs and, thus determine their 
specificity in a simple and fast manner. 
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4 OUTLOOK 
The findings obtained during this work demonstrate that sulfonated steroids actually do 
have a regulatory effect on CYP11A1 catalyzed reactions, especially on the interaction with 
the redox partner Adx. As the experiments were performed in-vitro with bovine enzymes 
expressed in bacteria and purified from there, these results are to be confirmed in an in-vivo
system using mammalian cells. Therefore, some challenges have to be overcome, as 
preliminary experiments utilizing SOAT-HEK293 cells showed. So far, it is not possible to 
detect CYP11A1-dependent cholesterol conversion in this cell line, since no cholesterol is 
translocated into the mitochondria, where CYP11A1 is located. Nevertheless, this cell line 
can be used to study the effect of sulfonated steroids on other CYPs involved in steroid 
hormone biosynthesis, as it was shown in the second publication forming this work. 
As the experiments were done using bovine enzymes, it would be of interest to switch to the 
human system. The bovine steroidogenic CYPs display a high homology with the human 
ones. Bovine CYP11A1 and CYP17A1 share 85 % and 86 % of their amino acid sequences with 
their human analogs, respectively. Moreover, the human and bovine steroidogenic CYPs 
both use the delta-5 pathway for the production of sex hormones, suggesting the bovine 
system to be a useful model system. Nevertheless, comparison of these systems will 
elucidate whether the bovine system serves as useful universal model or whether big 
differences between these species exist concerning the regulation of steroid hormone 
biosynthesis. Although the steroidogenic CYPs of bovine and human species are similar, 
differences in the activity and affinity of CYPs to their natural substrates were reported, 
suggesting differences of the bovine and the human system, when testing the influence of 
sulfonated steroids. To which extend this might occur has to be elucidated.  
In this work, an alternative pathway for sulfonated steroids was postulated involving 
CYP11A1 and CYP17A1. It starts with the conversion of CS and ends with the formation of 
17OH-PregS. As bovine enzymes and proteins were used for these experiments, the question 
arises, whether human CYPs behave similar or if 17OH-PregS is further metabolized.  
Further, investigations on CYP19A1 are of great interest. CYP19A1 forms E1 and E2 in 
mammals and represents a target for inhibitors used in breast cancer therapy. How DHEAS 
and E1S influence this enzyme is not known and should be studied in-vitro, to reveal the 
effect on a molecular level as well as in cell culture to postulate a physiological relevance.  
It was shown that the effect of DHEAS on CYP11A1, CYP17A1 and CYP21A2 differs. In the 
presence of DHEAS, CYP11A1 activity is enhanced, whereas CYP17A1- and CYP21A2-activities 
are not or only slightly inhibited. It would be interesting to analyze, whether sulfonated 
steroids have a regulatory effect on mitochondrial, but not on microsomal steroidogenic 
CYPs. For this reason, investigations of the role of DHEAS on mitochondrial CYP11B1 and 
CYP11B2, as well on microsomal CYP19A1 should be performed.   
Furthermore, the effect of sulfonated steroids on human CYP11A1 mutants displaying 
replacements in putative interaction sites with the redox partner, Adx, should be studied by 
expressing them in the SOAT-HEK293 cell culture system to analyze the influence which the 
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sulfonated steroids may have on these interactions and by this way on the modulation of the 
disease.  
In addition, it is conceivable to study, whether a correlation between phosphorylation of Adx 
and steroid sulfates exists. Adx can be phosphorylated by CK2, which introduces a negatively 
charged group and leads to an increased activity of CYP11A1 (similar to the effect of the 
negatively charged DHEAS). It would be interesting to see if steroid sulfates can further 
augment this activity. 
Taken together, further examinations of sulfonated steroids and their impact on 
steroidogenesis are highly interesting and very promising, as the results obtained so far 
indicate. 
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5 ABBREVIATIONS 
17OH-Preg(S) 17OH-Pregnenolone (sulfate)
17OH-Prog(S) 17OH-Progesterone (sulfate)
18OH-B 18OH-corticosterone
22(R)OH-C 22(R)OH-cholesterol
AdR Adrenodoxin reductase
Adx Adrenodoxin
Aldo Aldosterone
Andro Androstenedione
B Corticosterone
b5 Cytochrome b5
C Cholesterol
CAH Congenital adrenal hyperplasia
CPR NADPH-dependent 
oxidoreductase 
CS Cholesterol sulfate
CYP Cytochrome P450
DHEA Dehydroepiandrosterone
DHEAS Dehydroepiandrosterone sulfate
DOC 11-Deoxycorticosterone
E1 Estrone
E1S Estrone sulfate
E2 Estradiol
ER Endoplasmatic reticulum
F Cortisol
FAD Flavin adenine dinucleotide
FGly(S) Formylglycine (sulfate)
FMN Flavin mononucleotide
PAPS 3-phosphoadenosine-5-
phosphosulfate 
Preg Pregnenolone
PregS Pregnenolone sulfate
Prog Progesterone
RNA ribonucleic acid
RSS 11-deoxycortisol
StS Sulfatase
SULT Sulfotransferase
T(S) Testosterone (sulfate)
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6 APPENDIX
CYP17A1-DEPENDENT PRODUCT FORMATION IN THE PRESENCE OF SULFONATED DHEA
CYP17A1 catalyzes the conversion of Preg to 17OH-Preg and DHEA. In our reconstituted in-
vitro system CYP17A1 did not exhibit its lyase activity, because of the absence of b5. Here, 
we investigated the effect of DHEAS on the CYP17A1 catalyzed reaction on a molecular level.  
We examined the activity of CYP17A1 dependent 17-hydroxylation in the presence of 50 µM 
DHEAS at a Preg concentration of 10 µM. The evaluation of the HPLC data is shown in Figure 
A1. The amount of 17OH-Preg formed was 8.1 ± 0.5 µM for the control without DHEAS, and 
6.7 ± 0.9 µM for the sample incubated with 5-fold excess of DHEAS. Thus, DHEAS did not 
influence the activity of CYP17A1 in a significant manner. 
FIGURE A1: COMPARISON OF 17OH-PREG FORMATION BY CYP17A1 IN THE PRESENCE OF 5-FOLD EXCESS OF DHEA OR DHEAS (N=4 FOR 
EACH GROUP) 
CYP21A2-DEPENDENT PRODUCT FORMATION IN THE PRESENCE OF SULFONATED DHEA 
CYP21A2 hydroxylates Prog and 17OH-Prog at position C21. The activity of this reaction was 
explored in the presence of 50 µM DHEAS at a substrate concentration of 10 µM. In Figure 
A2 the evaluation of the HPLC data is displayed. Using Prog as substrate CYP21A2 formed 4.9 
± 0.7 µM DOC without DHEAS, and 4.8 ± 0.4 µM DOC when DHEAS was added to the system 
in a 5-fold excess. Utilizing 17OH-Prog CYP21A2 converted this substrate into 3.5 ± 0.1 µM 
RSS in the absence of DHEAS. When DHEAS was added to the system 3.2 ± 0.2 µM RSS were 
formed. 
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FIGURE A2: COMPARISON OF DOC AND RSS FORMATION BY CYP21A2 IN THE PRESENCE OF 5-FOLD EXCESS OF DHEA OR DHEAS (N=5 FOR 
EACH GROUP) 
CYP11A1-DEPENDENT CONVERSION OF 22(R)OH-C TO PREG IN THE PRESENCE OF DHEAS 
In the presence of DHEAS the catalytic efficiency of CYP11A1 is clearly enhanced as shown in 
the publication 2.1. In order to investigate whether the results obtained from these in-vitro
studies might possess a potential physiological relevance, cell culture experiments were 
conducted with SOAT-HEK293 cells recombinantly expressing CYP11A1 and Adx. Because of 
the insoluble nature of the substrate C, which was not possible convert in this cell culture 
system, 22(R)OH-C was chosen to be the substrate. The results showed that DHEAS did not 
influence the activity of CYP11A1 (Figure A3). The amount of Preg formed was 8.1 ± 03 µM 
for the control without DHEAS and 7.6 ± 0.5 µM for the sample with 75 µM DHEAS.  
FIGURE A3: CONVERSION OF 15 µM 22(R)OH-C IN SOAT-HEK293 CELLS BY CYP11A1. THE PRODUCT FORMATION ANALYZED BY HPLC IS 
REPRESENTED AS MEAN ± STANDARD DEVIATION OF FIVE INDIVIDUAL EXPERIMENTS. 
The next step was to explore whether the discrepancies between the in-vitro (publication 
2.1) and the cell culture experiments were due to the different substrates. Therefore, 
reconstituted in-vitro experiments were performed utilizing 22(R)OH-C as substrate. The 
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evaluation of the HPLC data is displayed in Figure A4.  The results showed that without 
DHEAS, 9.0 ±0.7 µM Preg were produced, which is similar to the product formation in the 
presence of DHEAS, where 9.0 ± 0.4 µM were obtained.  
FIGURE A12: CONVERSION OF 15 µM 22(R)OH-C IN A RECONSTITUTED IN-VITRO SYSTEM BY CYP11A1. THE PRODUCT FORMATION 
ANALYZED BY HPLC IS REPRESENTED AS MEAN ± STANDARD DEVIATION OF FIVE INDIVIDUAL EXPERIMENTS. 
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